



## Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,  
NAC Manimajra, Sector 13,  
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026

Date: 16<sup>th</sup> February, 2026

**The President**  
**Corporate Relationship Department**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**25<sup>th</sup> Floor, Dalal Street,**  
**Mumbai 400 001**

**The Vice President,**  
**Listing Compliance Department,**  
**National Stock Exchange of India Limited,**  
**Exchange Plaza, 5<sup>th</sup> Floor**  
**Plot No. C/2, G-Block,**  
**Bandra Kurla Complex, Bandra (E),**  
**Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUBJECT: PRESS RELEASE**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release titled as “Ind-Swift Laboratories Limited to Upgrade Samba Facility with an Investment of ₹400 Million for EU-GMP & PIC/S Compliance; Strengthen Global Export Strategy”.

Kindly take the above information on record.

Thanking you,  
For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA**  
**VP-CORPORATE AFFAIRS &**  
**COMPANY SECRETARY**  
Encl: a/a



### Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

## PRESS RELEASE

### **IND-SWIFT LABORATORIES LIMITED TO UPGRADE SAMBA FACILITY WITH AN INVESTMENT OF ₹400 MILLION FOR EU-GMP & PIC/S COMPLIANCE; STRENGTHEN GLOBAL EXPORT STRATEGY**

#### **UNIT TO CONTRIBUTE ₹750-800 MILLION FROM FY 2027-28 ONWARDS**

Chandigarh based Ind-Swift Laboratories Limited, has approved a capital investment of approximately ₹400 million to upgrade its finished dosage manufacturing facility located at Samba, Jammu & Kashmir. With this investment, the facility will be enhanced to meet international regulatory standards, primarily EU-GMP and PIC/S, enabling the site to cater to regulated export markets.

Proposed enhancements will improve environmental sustainability, strengthen material governance, and enhance utility reliability across the facility. The company assumes to complete this upgradation within a span of 8-12 months. Upon completion, the Company envisages to receive EU GMP approval within 8-9 months & plans to simultaneously file approx. 15-20 molecules across Europe & UK, Australia, Canada and South Africa.

The existing ointment section is currently catering to the domestic market which includes manufacturing of own brands, contract manufacturing. Other dosage forms like tablets, capsules, dry syrups are also supplied from this facility. The unit generates an annual sales of ₹ 360 million with a bottom line of an average 10%.

Ind-Swift aims to generate an overall sales of close to ₹ 750-800 Million & a strong bottom line of 18-20% of revenues with this investment from FY 27-28 onwards. Targeted infrastructure modifications and upgradation will improve process robustness, minimize manual intervention, reinforce data integrity, and ensure consistent high-quality output.

Overall, these initiatives are designed to future-proof the facility, enable scalable growth, elevate global compliance readiness, and reinforce patient safety and long-term business sustainability.

#### **Confirming the development, Mr. Sahil Munjal, Managing Director (Exports), stated:**

“We are witnessing increased demand for our products in the export markets. The upgradation of the Jammu facility will enable us to expand our product portfolio in Europe, UK, Australia and other markets, significantly strengthening our global footprint.”

The Samba facility upgrade represents a significant milestone in Ind-Swift’s transformation journey, reinforcing its commitment to regulatory excellence, export-led growth, and sustainable value creation.

#### **Financial Performance Highlights**

##### **Earlier, the Company announced its financial results for the third quarter of FY26.**

- Operating EBITDA increased by 6.60% quarter-on-quarter to ₹9.11 crore
- Profit After Tax increased by 22.67% to ₹10.74 crore
- Total Revenue grew by 5.21% to ₹177.06 crore

##### **For the nine months ended FY26:**

- Total Income stood at ₹507.93 crore
- Operating EBITDA stood at ₹26.09 crore

- Profit After Tax stood at ₹27.62 crore

### **Strategic Business Transformation**

Following the successful ₹1,650 crore divestment of its API and CRAMS businesses and the subsequent merger with Ind-Swift Limited, the Company is steadily transitioning into a lean, net debt-free organization with a focused Pure-Play Formulations Export and Contract Development & Manufacturing (CDM) platform.

---

---

**FOR FURTHER INFORMATION PLEASE CONTACT:**

**PARDEEP VERMA**

**VP-CORPORATE AFFAIRS AND**

**COMPANY SECRETARY**

**M.NO. +91-9814131627**

**E-MAIL ID: INVESTOR@INDSWIFTLABS .COM**